```
     (FILE 'HOME' ENTERED AT 10:01:37 ON 10 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 10:01:43 ON 10 MAY 2005
L1           1 S ARIPIPRAZOLE/CN

     FILE 'REGISTRY' ENTERED AT 10:02:46 ON 10 MAY 2005

     FILE 'CAPLUS' ENTERED AT 10:02:59 ON 10 MAY 2005
               E NERURKAR MANOJ/IN,AU
L2             6 S E3-6
               E NARINGREKAR VIJAY/IN,AU
L3             9 S E2-7
               E DOMINICK MARK/IN,AU
L4            23 S E2-6
L5            36 S L2 OR L3 OR L4
L6           168 S ARIPIPRAZOLE
L7         28099 S CYCLODEXTRIN
L8         11224 S ANTIPSYCHOTIC OR ANTI-PSYCHOTIC
L9             3 S L5 AND (L6 OR L7 OR L8)
```

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:117668 CAPLUS
TITLE: Multidisciplinary investigation of atypical inclusion complexes of β- cyclodextrin and a phospholipase-A2 inhibitor
AUTHOR(S): Dahlheim, C. E.; Dali, M. M.; **Naringrekar, V.** H.; Miller, S. A.; Shukla, R. B.
CORPORATE SOURCE: Pharmaceutical Research Institute, Bristol-Myers Squibb, New Brunswick, NJ, 08903-0191, USA
SOURCE: Journal of Pharmaceutical Sciences (2005), 94(2), 409-422
CODEN: JPMSAE; ISSN: 0022-3549
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB BMS-188184, an anthracene derivative, has been found to form at least two complexes with β- cyclodextrin. The association/dissociation kinetics of the two complexes were extremely slow, with one complex requiring approx. 24 h, and the other complex requiring more than 8 wk, to reach equilibrium The stability consts. of the two complexes were estimated at approx. 11,000 and 39,000 M-1 under nonequil. conditions. The slow rates of dissociation allowed the complexes and the unbound BMS-188184 to be separated using high-performance liquid chromatog. Exact mass liquid chromatog./mass spectrometry, tandem mass spectrometry, and NMR techniques were used to characterize the stoichiometry of both complexes as 1:1. Because of the ability of the complexes to survive high-performance liquid chromatog. anal., their slow reaction rates, and 1:1 stoichiometry, the complexes were tentatively characterized as [2]-rotaxanes. The available data suggest that the two complexes are conformational isomers.
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:182652 CAPLUS
DOCUMENT NUMBER: 140:223300
TITLE: **Aripiprazole** complex formulation and method
INVENTOR(S): **Nerurkar, Manoj; Naringrekar, Vijay ; Dominick, Mark**
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017897	A2	20040304	WO 2003-US25573	20030814
WO 2004017897	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004077594	A1	20040422	US 2003-642366	20030814
PRIORITY APPLN. INFO.:			US 2002-404713P P	20020820

AB An **aripiprazole** formulation is provided which includes the **antipsychotic** agent **aripiprazole** in the form of an inclusion complex in a β- **cyclodextrin**, preferably, sulfobutyl ether β- **cyclodextrin** (SBECD), which in the form of an injectable produces reversible, generally minimal-to-mild irritation at the i.m. injection site. A method for minimizing or reducing irritation caused by **aripiprazole** at an i.m. injection site and a method for treating schizophrenia employing the above formulation are also provided.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:375405 CAPLUS
DOCUMENT NUMBER: 131:49456

TITLE: Injectable antifungal formulations containing β-cyclodextrin derivatives
INVENTOR(S): **Naringrekar, Vijay H.**
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9927932	A1	19990610	WO 1998-US24938		19981130
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9915983	A1	19990616	AU 1999-15983		19981130
PRIORITY APPLN. INFO.:			US 1997-980950	A	19971201
			WO 1998-US24938	W	19981130

OTHER SOURCE(S): MARPAT 131:49456

AB A pharmaceutical composition suitable for parenteral administration comprising an antifungally effective amount of a compound represented by formula I, wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C4-5) alkyl group substituted by a hydroxy moiety; and an effective amount of maltosyl-β- **cyclodextrin** or glucosyl-β-**cyclodextrin** (II), is disclosed. A solution containing II 200, and a difluorophenyl priprazinylphenoxymethyltriazol derivative (III) 12.5 mg/mL was prepared The solubility of III was 11.9 mg/mL.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT